Commonwealth Equity Services LLC Sells 1,519 Shares of Schrödinger, Inc. (NASDAQ:SDGR)

Commonwealth Equity Services LLC lessened its position in Schrödinger, Inc. (NASDAQ:SDGR) by 2.5% in the fourth quarter, HoldingsChannel reports. The fund owned 59,297 shares of the company’s stock after selling 1,519 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Schrödinger were worth $1,144,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. increased its holdings in Schrödinger by 60.2% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,510,518 shares of the company’s stock worth $67,718,000 after buying an additional 1,319,464 shares during the last quarter. Barclays PLC lifted its stake in Schrödinger by 421.6% in the third quarter. Barclays PLC now owns 107,554 shares of the company’s stock worth $1,995,000 after purchasing an additional 86,933 shares during the last quarter. Stephens Investment Management Group LLC increased its stake in shares of Schrödinger by 4.4% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,607,656 shares of the company’s stock worth $31,012,000 after buying an additional 67,786 shares during the period. State Street Corp increased its stake in shares of Schrödinger by 1.8% during the third quarter. State Street Corp now owns 2,155,620 shares of the company’s stock valued at $39,987,000 after buying an additional 38,972 shares during the period. Finally, Avanza Fonder AB purchased a new position in shares of Schrödinger during the 4th quarter worth approximately $577,000. Institutional investors own 79.05% of the company’s stock.

Insider Activity

In related news, CFO Geoffrey Craig Porges sold 5,491 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $21.76, for a total value of $119,484.16. Following the transaction, the chief financial officer now directly owns 27,544 shares of the company’s stock, valued at $599,357.44. This represents a 16.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 8.60% of the company’s stock.

Schrödinger Stock Performance

Shares of Schrödinger stock opened at $19.74 on Tuesday. Schrödinger, Inc. has a one year low of $16.67 and a one year high of $29.15. The stock has a 50 day moving average price of $23.12 and a 200-day moving average price of $20.78. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -8.44 and a beta of 1.62.

Schrödinger (NASDAQ:SDGR) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). The firm had revenue of $88.32 million during the quarter, compared to analysts’ expectations of $83.20 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. Sell-side analysts predict that Schrödinger, Inc. will post -2.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SDGR has been the subject of several analyst reports. Piper Sandler reduced their price target on Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. KeyCorp upped their target price on shares of Schrödinger from $25.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $32.29.

Schrödinger Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.